US Indapamide Market to reach $261.3 million by 2035

US indapamide market was valued at $203.0 million in 2025 and is projected to reach $261.3 million by 2035, growing at a CAGR of 2.6% during 2026 to 2035. The rising prevalence of hypertension and cardiovascular diseases in the United States is a key factor driving demand for effective antihypertensive medications such as indapamide. As a thiazide-like diuretic, indapamide plays a critical role in blood pressure management, particularly in patients requiring long-term therapy and combination treatment approaches. Increasing awareness of early diagnosis, along with expanding treatment adherence initiatives, is further supporting consistent prescription volumes across the country.

Browse the full report description of “US Indapamide Market Size, Share & Trends Analysis Report, By Product Type (Immediate-Release Indapamide, Sustained/Extended-Release Indapamide), By Dosage Strength (1.25 mg, 2.5 mg, Other customized/compounded doses), By Application (Hypertension, Edema, Cardiovascular Risk Management), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/us-indapamide-market

Immediate-release and sustained/extended-release formulations are witnessing steady adoption, with healthcare providers increasingly preferring tailored dosing strategies based on patient profiles. Among applications, hypertension remains the dominant segment, while cardiovascular risk management is gaining traction due to the growing focus on preventive care. The continued burden of chronic conditions and the aging population is reinforcing long-term demand for indapamide-based therapies across the US healthcare system.

Rising Hypertension Burden and Federal Health Initiatives Driving Demand

In the United States, the growing incidence of hypertension is significantly contributing to the expansion of the indapamide market. According to the Centers for Disease Control and Prevention, nearly 48.1% of adults (approximately 119.9 million people) had hypertension between 2021 and 2023, with only about 1 in 4 adults having their condition under control. This substantial treatment gap continues to drive demand for effective and well-tolerated antihypertensive medications, including indapamide.

Furthermore, national initiatives such as the Million Hearts® program, led by the U.S. Department of Health and Human Services, have been actively promoting cardiovascular disease prevention strategies through 2023–2026. These programs emphasize improved hypertension control, medication adherence, and risk reduction, directly supporting the increased utilization of diuretics in clinical practice. As healthcare systems focus on reducing cardiovascular morbidity and mortality, the role of indapamide in combination therapies and long-term hypertension management continues to strengthen, sustaining market growth.

Pharmaceutical Strategies and Generic Expansion Supporting Market Growth

The US indapamide market is characterized by strong participation from generic pharmaceutical manufacturers, ensuring wide accessibility and cost-effective treatment options. Key players include Teva Pharmaceuticals, Viatris Inc., Sandoz, Sun Pharmaceutical Industries, and Dr. Reddy’s Laboratories.

• In August 2025, Piramal Pharma Solutions partnership with George Medicines marked a significant development in the U.S. indapamide market with the FDA approval of WIDAPLIK in June 2025. This innovative triple-combination drug (telmisartan, amlodipine, and indapamide) is the first of its kind approved for initial hypertension treatment, enhancing therapeutic efficiency. Leveraging its integrated CDMO capabilities, Piramal supported end-to-end development and manufacturing, enabling faster commercialization.

• In May 2025, Teva Pharmaceutical Industries Ltd. reinforced its growth strategy in the U.S. indapamide market through its strong generics and biosimilars portfolio, emphasizing continued expansion and new product launches. The company’s “Pivot to Growth” acceleration phase highlights increased investment in complex generics, supporting sustained revenue growth across regions.

Market Coverage

• The market number available for – 2025–2035
• Base year – 2025
• Forecast period – 2026–2035
• Segment Covered –
  • By Product Type
  • By Dosage Strength
  • By Application
  • Competitive Landscape – Teva Pharmaceuticals, Viatris Inc., Sandoz, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, among others

Key Questions Addressed by the Report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• Who are the key players in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

US Indapamide Market Segment

By Product Type

• Immediate-Release Indapamide
• Sustained/Extended-Release Indapamide

By Dosage Strength

• 25 mg
• 5 mg
• Other Customized/Compounded Doses

By Application

• Hypertension
• Edema (Fluid Retention)
• Cardiovascular Risk Management

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/us-indapamide-market